Monte Rosa Therapeutics Inc (GLUE)

Apr 28, 2025

Monte Rosa reports breakthrough in breast cancer treatment - Investing.com Australia

Apr 28, 2025

Apr 28, 2025

Monte Rosa reports breakthrough in breast cancer treatment By Investing.com - Investing.com South Africa

Apr 28, 2025

Apr 28, 2025

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough: New Molecular Glue Degrader Achieves 77% Tumor Shrinkage in Hard-to-Treat Breast Cancer - Stock Titan

Apr 28, 2025

Apr 26, 2025

Monte Rosa Therapeutics Inc (GLUE) Sits And Waits For Direction At $5.06 Price - Stocksregister

Apr 26, 2025

Apr 25, 2025

Geode Capital Management LLC Lowers Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 25, 2025

Apr 24, 2025

Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Market Watch Highlights: Monte Rosa Therapeutics Inc (GLUE) Ends on an Upturn Note at 5.33 - DWinneX

Apr 24, 2025

Apr 24, 2025

GLUE’s 2023 Market Dance: Down -23.20% – Time to Invest? - investchronicle.com

Apr 24, 2025

Apr 22, 2025

How To Trade (GLUE) - news.stocktradersdaily.com

Apr 22, 2025

Apr 22, 2025

Monte Rosa Therapeutics Insider Ups Holding During Year - Yahoo Finance

Apr 22, 2025

Apr 20, 2025

Franklin Resources Inc. Buys Shares of 27,510 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 20, 2025

Apr 16, 2025

Vanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 16, 2025

Apr 14, 2025

Wellington Management Group LLP Grows Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 14, 2025

Apr 13, 2025

American Century Companies Inc. Has $533,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 13, 2025

Apr 12, 2025

Sei Investments Co. Buys Shares of 17,236 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 12, 2025

Apr 06, 2025

How to Take Advantage of moves in (GLUE) - news.stocktradersdaily.com

Apr 06, 2025

Mar 29, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025

Mar 27, 2025

Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st

Mar 27, 2025

Mar 26, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com India

Mar 26, 2025

Mar 25, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com

Mar 25, 2025

Mar 25, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World

Mar 25, 2025

Mar 24, 2025

Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha

Mar 24, 2025

Mar 24, 2025

FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World

Mar 24, 2025

Mar 23, 2025

Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World

Mar 23, 2025

Mar 22, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 22, 2025

Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World

Mar 22, 2025

Mar 22, 2025

Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks

Mar 22, 2025

Mar 22, 2025

Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN

Mar 22, 2025

Mar 21, 2025

Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks

Mar 21, 2025

Mar 21, 2025

Positive signs for Monte Rosa in early data - The Pharma Letter

Mar 21, 2025

Mar 20, 2025

Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com

Mar 20, 2025

Mar 20, 2025

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Files $400 Million Mixed Shelf - MarketScreener

Mar 20, 2025

Mar 20, 2025

Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com

Mar 20, 2025

Mar 20, 2025

MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks

Mar 20, 2025

Mar 20, 2025

Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks

Mar 20, 2025